Ponesimod

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Retrieved on: 
Tuesday, March 26, 2024
Professional Services, Health, Neurology, Finance, Pharmaceutical, Biotechnology, AbbVie, MRI, AstraZeneca, Actelion, Disease, Multiple sclerosis, Ponesimod, Partnership, Novartis, Patient, RMS, Acquisition, DMT, Woman, Johnson & Johnson, Patent, Fatigue, Marketing, Pharmaceutical industry

To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals.

Key Points: 
  • To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals.
  • “We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals.
  • Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients.
  • Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.

Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.

Retrieved on: 
Friday, January 26, 2024
Multiple sclerosis, Janssen, Actelion, Orange Book, Food, Ponesimod, Vanda, The Orange Book, Patent, Pharmaceutical industry

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.
  • When issued, this patent is anticipated to expire on October 10, 2042.
  • Upon issuance, Vanda intends to list this patent in the U.S. Food and Drug Administration publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
  • Vanda acquired rights to U.S. and Canadian rights to PONVORY® from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

Retrieved on: 
Thursday, December 7, 2023
Woman, RMS, Health Canada, Acquisition, Food, Lymphocyte, Psoriasis, Stifel, Ponesimod, FDA, Ulcerative colitis, Multiple sclerosis, Trial of the century, Janssen, Disability, Actelion, Vanda, Pharmaceutical industry

WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.

Key Points: 
  • WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.
  • PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
  • PONVORY® has a proven safety profile with over 10 years of data.
  • Stifel acted as exclusive financial advisor to Vanda with respect to this acquisition.

Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, February 27, 2023
Online, Optic nerve, Hospital, PDF, Pharmacy, Table, Online and offline, Optic neuritis, Risk, Ponesimod, Investment, Distribution, Growth, Government, COVID-19, Ozanimod, Prevalence, Pharmaceutical industry, Glaucoma, Others, Indication

PORTLAND, Ore., Feb. 27, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Optic Nerve Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators Therapy, Others Treatment Type), by Indication (Optic Neuritis, Glaucoma, Optic Nerve Atrophy, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global optic nerve disorder treatment industry generated $3,372.46 million in 2021, and is estimated to reach $5,247.82 million by 2031, witnessing a CAGR of 4.5% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • Increase in prevalence of optic nerve disorder treatment, growth in geriatric population and increase in technological advancement drive the growth of the global optic nerve disorder treatment market.
  • PORTLAND, Ore., Feb. 27, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " Optic Nerve Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators Therapy, Others Treatment Type), by Indication (Optic Neuritis, Glaucoma, Optic Nerve Atrophy, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the global optic nerve disorder treatment industry generated $3,372.46 million in 2021, and is estimated to reach $5,247.82 million by 2031, witnessing a CAGR of 4.5% from 2022 to 2031.
  • Impact of Covid-19 on Optic Nerve Disorder Treatment Market:
    Decrease in the demand for optic nerve treatment due to the risk of Covid-19 infection had a negative impact on the global optic nerve disorder treatment market, especially during the lockdown period.

Novartis' Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada According to Surveyed Neurologists in Spherix Report

Retrieved on: 
Thursday, May 26, 2022
Physician, Diroximel fumarate, BMS, Dermatology, Ponesimod, Patient, Nephrology, Mark (given name), CDEC, Neurology, Novartis, Research, Gastroenterology, HCP, DMF, MS, Roche, Multiple sclerosis, DMT, Growth, Parallel, Pharmaceutical industry, Retail, Ozanimod, Dimethyl fumarate, EU, Biogen

EXTON, Pa., May 26, 2022 /PRNewswire/ -- Following an eventful 2021 that included the launch of two new brands—Novartis' Kesimpta and BMS' Zeposia—and generic versions of Biogen's Tecfidera, the Canadian multiple sclerosis (MS) market appears to be settling into patterns of strong uptake of new therapies.

Key Points: 
  • Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the MS market in Canada through their RealTime Dynamix: Multiple Sclerosis (Canada) service since 2019.
  • Below are a few key insights:
    Capitalizing on recent positive pCPA2 negotiations for Mayzent (October 2021) and Kesimpta (March 2022), Novartis has seen strong growth for its MS portfolio in Canada.
  • Neurologists report the greatest recognized increase in promotional efforts for these brands and the highest frequency of recent sales representative interaction.
  • The Q2 2022 report is the seventh semiannual edition included in the RealTime Dynamix: Multiple Sclerosis (Canada) service.

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

Retrieved on: 
Tuesday, February 8, 2022
Fabry disease, Cerebral vasospasm, Hypertension, Letter, European Medicines Agency, Binge eating disorder, Essential tremor, AGM, Standard Business Reporting, Annual, ASAH, Lupus, REACT, The Lancet, Research, COVID-19, FDA, Neurocrine Biosciences, Method, Epilepsy, CARE, Drug discovery, Night, Risk, Patient, Review, IDIA, EMA, SIX Swiss Exchange, Janssen Pharmaceuticals, Documentation, Johnson & Johnson, Insomnia, Result, Ponesimod, Income, Science, Board, Annual report, CMO, Heart, Janssen Biotech, Population, CEO, Mission statement, Corporation, Intelligence, Vaccine, Pharmaceutical industry, Animal, Online gambling, Security (finance), Renewable energy, Fine chemical, Management, Risk management, Shareholder, Actelion

Idorsia created 268 new positions worldwide in 2021, bringing the total number of employees (permanent, post-doc, and apprentices) to 1176 (2020: 908).

Key Points: 
  • Idorsia created 268 new positions worldwide in 2021, bringing the total number of employees (permanent, post-doc, and apprentices) to 1176 (2020: 908).
  • My role and that of the Board is to provide direction and oversight, as well as governance of the organization.
  • We are building Idorsia with a long-term focus, and we run the company in a responsible and sustainable way.
  • In 2021, we made great strides toward realizing our vision of creating a sustainable mid-sized biopharmaceutical company based on innovation.

New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM▼ (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Retrieved on: 
Wednesday, October 13, 2021
Oncology, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Johnson & Johnson, Congress, European Committee of the Regions, Ebola virus disease treatment research, Multiple sclerosis, Janssen Pharmaceuticals, EDSS, Research, Ponesimod, CLS, ARR, Pharmaceutical industry

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a new subgroup analysis of the pivotal Phase 3 OPTIMUM trial.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a new subgroup analysis of the pivotal Phase 3 OPTIMUM trial.
  • Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population.
  • Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population.
  • Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.

European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

Retrieved on: 
Monday, May 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Clinical trials, Immunosuppressants, Medical specialties, Multiple sclerosis, Immunology, Medicine, Nitriles, Teriflunomide, Sphingosine-1-phosphate, Janssen Pharmaceuticals, Ponesimod, S1PR1, Sphingosine-1-phosphate receptor modulator, Multiple Sclerosis, PONVORY (ponesimod), the Janssen Pharmaceutical Companies of Johnson & Johnson, MULTIPLE SCLEROSIS, PONVORY (PONESIMOD), THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.
  • Janssen Receives Positive CHMP Opinion for PONVORY (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features.
  • 11 DAmbrosio D, Feedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.

Janssen Receives Positive CHMP Opinion for PONVORY™ ▼ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features

Retrieved on: 
Friday, March 26, 2021
Biotechnology, Health, Pharmaceutical, Managed care, Oncology, Multiple sclerosis, Immunosuppressants, Medical specialties, Johnson & Johnson, Health care, Medicine, Beerse, Janssen Pharmaceuticals, Medical research, Janssen, Ponesimod, Ponesimod, Multiple Sclerosis, the Janssen Pharmaceutical Companies of Johnson & Johnson

If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS.

Key Points: 
  • If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS.
  • If approved, ponesimod will be the first therapy by Janssen for patients living with RMS with active disease defined by clinical or imaging features.
  • Janssen Research & Development, LLC and Janssen Pharmaceutica NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Janssen Submits European Marketing Authorisation Application for Ponesimod for Treatment of Adults with Relapsing Multiple Sclerosis.

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions

Retrieved on: 
Friday, March 19, 2021
Multiple sclerosis, Medical specialties, Organ systems, Autoimmune diseases, Immunosuppressants, Management of multiple sclerosis, Actelion, Immunology, Ponesimod

Those results, combined with a favorable side effect profile, make ponesimod a useful treatment option for people with relapsing MS," said Robert J.

Key Points: 
  • Those results, combined with a favorable side effect profile, make ponesimod a useful treatment option for people with relapsing MS," said Robert J.
  • Fox, M.D., Staff Neurologist, Mellen Center for MS Treatment and Research, Vice-Chair for Research, Neurological Institute, Cleveland Clinic.
  • Dr. Fox has served as a paid consultant to Actelion Pharmaceuticals Ltd and Janssen as a member of the ponesimod Advisory Board.
  • Your healthcare provider should review a recent blood test of your white blood cells before you start taking PONVORY.